Cigna director granted 782 common shares

Cigna Group director Michael J. Hennigan received a grant of 782 shares of Common Stock on April 22, 2026.

Rhea-AI Filing Summary

Cigna Group director Michael J. Hennigan received a grant of 782 shares of Common Stock on April 22, 2026. The shares were acquired as a compensation-related grant or award at a stated price of $0.0000 per share. Following this transaction, he directly holds 1,350 shares of Cigna Group common stock.

Insider Trade Summary

Grant/Award: 782 shares

Grant/Award 1 txn

Insider Hennigan Michael J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $.01 Par Value	782	$0.00	$0.00

Holdings After Transaction: Common Stock, $.01 Par Value — 1,350 shares (Direct)

Key Figures

Shares granted: 782 shares Price per granted share: $0.0000 per share Total shares held after transaction: 1,350 shares

3 metrics

Shares granted 782 shares Grant, award, or other acquisition on April 22, 2026

Price per granted share $0.0000 per share Stated transaction price for awarded common stock

Total shares held after transaction 1,350 shares Director’s direct ownership following the award

Key Terms

Form 4, Common Stock, $.01 Par Value, Grant, award, or other acquisition

3 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock, $.01 Par Value financial

"security_title: "Common Stock, $.01 Par Value""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cigna Group (CI) report for Michael J. Hennigan?

Cigna Group reported that director Michael J. Hennigan acquired 782 shares of Common Stock as a grant or award. The transaction was coded as an acquisition on April 22, 2026, and reflects a compensation-related share award rather than an open-market purchase.

How many Cigna Group (CI) shares does Michael J. Hennigan hold after this Form 4 filing?

After the reported transaction, Michael J. Hennigan directly holds 1,350 shares of Cigna Group Common Stock. This figure includes the newly granted 782 shares and represents his total direct ownership position as shown in the filing after the award.

What does the acquisition code "A" mean in the Cigna Group (CI) Form 4?

In this Cigna Group Form 4, transaction code "A" is described as a grant, award, or other acquisition. It indicates that the 782 shares were received as a compensation-related award, not bought in the open market, with a stated price of $0.0000 per share.

Was the Cigna Group (CI) insider transaction a market buy or a share award?

The transaction was a share award, not a market buy. The filing labels the event as a grant, award, or other acquisition of 782 shares at a price of $0.0000 per share, indicating compensation rather than an open-market purchase of Cigna Group stock.

Does the Cigna Group (CI) Form 4 show any stock sales by Michael J. Hennigan?

The provided Form 4 data shows only one transaction coded as an acquisition for 782 shares and no sales. The transactionSummary section reports zero sell transactions and a neutral net buy-sell share count for this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hennigan Michael J

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CONNECTICUT 06002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	04/22/2026		A		782	A	$0	1,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	Tyler Gratton, attorney-in-fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)